I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

EADV 2025 | Sep 17, 2025 - Sep 20, 2025

Immunology

Sanofi is committed to advancing the science of immunology through our research and development of innovative therapies for patients with chronic, difficult-to-treat, inflammatory diseases.

Available rooms
1 of 1

  • Atopic Dermatitis

    Atopic dermatitis is a chronic, predominantly type 2 inflammatory disease characterized by intense itch, skin lesions, and increased risk of infections, barrier dysfunction, and poor quality of life.

  • Hidradenitis Suppurativa

  • Early Pipeline